I think you read updates to the brief today based on this new entry - but I will re-iterate to see notes from today.
#79 and #78 are the really getting the concept. I do not have team feedback but they may feel the spiral looks a little like DNA (not accurate for our research really?). We also want to be able to add the company name somewhere. I am ranking these high to re-enforce the focus on U and I but see the notes below and in the brief again.
I would say that feedback was on less focus on hexagon, more focus on the U and the I or even tying them together somehow, making them stand out as a combo....We decided to use GENUINE or another name RUBICON for our first trial and UNITY for a different trial (combines Ublituximab and TGR-1202 for U and T).
That said however - for GENUINE - remember the importance of the U and the I being key. We like the word and what it stands for - we see the chance to highlight "our" drug with "U" (an antibody) and the idea of a combo with the I drug (a BCR receptor inhibitor of BTK - less important). Maybe even tying them together somehow. Please see the updated comments at brief about that and also about focusing on the science behind the drugs possibly (shapes of the pathways inhibited - search antiCD20 antibody or BCR receptor) in the logo or any design element. It is valuable feedback from our CEO, COO and team to make a decision with me. THANKS AGAIN!